Myozyme® (alglucosidase alfa) + Myozyme® (alglucosidase alfa)
ApprovedTerminated 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pompe Disease
Conditions
Pompe Disease, Glycogen Storage Disease Type II (GSD-II), Glycogenesis 2 Acid Maltase Deficiency
Trial Timeline
Dec 14, 2008 → Feb 18, 2020
NCT ID
NCT00701701About Myozyme® (alglucosidase alfa) + Myozyme® (alglucosidase alfa)
Myozyme® (alglucosidase alfa) + Myozyme® (alglucosidase alfa) is a approved stage product being developed by Sanofi for Pompe Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT00701701. Target conditions include Pompe Disease, Glycogen Storage Disease Type II (GSD-II), Glycogenesis 2 Acid Maltase Deficiency.
What happened to similar drugs?
9 of 16 similar drugs in Pompe Disease were approved
Approved (9) Terminated (3) Active (6)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00701701 | Approved | Terminated |
Competing Products
20 competing products in Pompe Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| S-606001 + Placebo | Shionogi | Phase 2 | 42 |
| alglucosidase alfa | Sanofi | Approved | 43 |
| GZ402666 | Sanofi | Phase 1 | 29 |
| alglucosidase alfa + Placebo | Sanofi | Phase 3 | 40 |
| alglucosidase alfa | Sanofi | Approved | 43 |
| glucosidase alfa | Sanofi | Pre-clinical | 26 |
| Alglucosidase alfa | Sanofi | Approved | 35 |
| Avalglucosidase Alfa | Sanofi | Phase 2 | 35 |
| alglucosidase alfa | Sanofi | Approved | 43 |
| Myozyme | Sanofi | Phase 3 | 40 |
| alglucosidase alfa | Sanofi | Approved | 43 |
| alglucosidase alfa | Sanofi | Pre-clinical | 26 |
| Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) | Sanofi | Phase 3 | 40 |
| ALGLUCOSIDASE ALFA | Sanofi | Approved | 43 |
| alglucosidase alfa + alglucosidase alfa | Sanofi | Approved | 35 |
| Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) | Sanofi | Phase 2 | 39 |
| Myozyme | Sanofi | Phase 2 | 35 |
| Myozyme | Sanofi | Phase 2 | 35 |
| recombinant human acid alpha-glucosidase (rhGAA) | Sanofi | Phase 2 | 35 |
| Alglucosidase Alfa + Methotrexate + Rituximab | Sanofi | Approved | 43 |